JP2025502377A5 - - Google Patents

Info

Publication number
JP2025502377A5
JP2025502377A5 JP2024542357A JP2024542357A JP2025502377A5 JP 2025502377 A5 JP2025502377 A5 JP 2025502377A5 JP 2024542357 A JP2024542357 A JP 2024542357A JP 2024542357 A JP2024542357 A JP 2024542357A JP 2025502377 A5 JP2025502377 A5 JP 2025502377A5
Authority
JP
Japan
Prior art keywords
atom
group
hydrogen atom
cancer
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502377A (ja
Filing date
Publication date
Priority claimed from EP22305031.1A external-priority patent/EP4212531A1/en
Application filed filed Critical
Publication of JP2025502377A publication Critical patent/JP2025502377A/ja
Publication of JP2025502377A5 publication Critical patent/JP2025502377A5/ja
Pending legal-status Critical Current

Links

JP2024542357A 2022-01-14 2023-01-13 アザインドール誘導体、及びerkキナーゼ阻害剤としてのそれらの使用 Pending JP2025502377A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305031.1 2022-01-14
EP22305031.1A EP4212531A1 (en) 2022-01-14 2022-01-14 Azaindole derivatives and their use as erk kinase inhibitors
PCT/EP2023/050692 WO2023135233A1 (en) 2022-01-14 2023-01-13 Azaindole derivatives and their use as erk kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2025502377A JP2025502377A (ja) 2025-01-24
JP2025502377A5 true JP2025502377A5 (cg-RX-API-DMAC7.html) 2026-01-26

Family

ID=80445694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542357A Pending JP2025502377A (ja) 2022-01-14 2023-01-13 アザインドール誘導体、及びerkキナーゼ阻害剤としてのそれらの使用

Country Status (16)

Country Link
US (3) US11827637B2 (cg-RX-API-DMAC7.html)
EP (2) EP4212531A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502377A (cg-RX-API-DMAC7.html)
KR (1) KR20240134887A (cg-RX-API-DMAC7.html)
CN (1) CN118541370A (cg-RX-API-DMAC7.html)
AR (1) AR128267A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023207276A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242894A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002070A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024008809A2 (cg-RX-API-DMAC7.html)
IL (1) IL314199A (cg-RX-API-DMAC7.html)
JO (1) JOP20240157A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008629A (cg-RX-API-DMAC7.html)
TW (1) TW202334147A (cg-RX-API-DMAC7.html)
UA (1) UA130477C2 (cg-RX-API-DMAC7.html)
WO (1) WO2023135233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2025012357A1 (en) * 2023-07-12 2025-01-16 Ipsen Pharma Fluorinated azaindole derivatives and their use as erk kinase inhibitors
WO2025012386A1 (en) * 2023-07-12 2025-01-16 Agv Discovery Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
AU2024297019A1 (en) * 2023-07-12 2026-01-22 Agv Discovery Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
EP4588918A1 (en) 2024-01-18 2025-07-23 AGV Discovery Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one
WO2026064271A1 (en) 2024-09-23 2026-03-26 Fmc Corporation Substituted bicyclic amide derivatives as herbicides
WO2026153964A1 (en) * 2025-01-15 2026-07-23 Ipsen Pharma Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one for use in the treatment of melanoma with braf v600 mutation
WO2026153950A1 (en) 2025-01-15 2026-07-23 Ipsen Pharma Pharmaceutical compositions comprising (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one hydrochloride and at least one carboxylic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
US8697697B2 (en) 2011-01-04 2014-04-15 Kinentia Biosciences Llc Pyrazole derivatives as ERK inhibitors
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2909206A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
CN113423707A (zh) * 2018-11-16 2021-09-21 加利福尼亚技术学院 Erk抑制剂及其用途
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Similar Documents

Publication Publication Date Title
AU2019414550B2 (en) FAK inhibitor and drug combination thereof
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP2014517017A5 (ja) 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用
JP2018516917A5 (cg-RX-API-DMAC7.html)
JP2013525458A5 (cg-RX-API-DMAC7.html)
JP2021519783A5 (cg-RX-API-DMAC7.html)
JP2016513660A5 (cg-RX-API-DMAC7.html)
CN108366979B (zh) 与泛素化-蛋白酶体系统有关的化合物及医药组合物
CN110582489A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP2010539110A5 (cg-RX-API-DMAC7.html)
JP2008528467A5 (cg-RX-API-DMAC7.html)
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2010539095A5 (cg-RX-API-DMAC7.html)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2007511504A5 (cg-RX-API-DMAC7.html)
JP2019529444A5 (cg-RX-API-DMAC7.html)
JP2013056930A5 (cg-RX-API-DMAC7.html)
JP2021502387A5 (cg-RX-API-DMAC7.html)
JP2017502092A5 (cg-RX-API-DMAC7.html)
JP2016505063A (ja) ソルチリン阻害剤としてのn置換された5置換フタルアミド酸
JP2005505618A5 (cg-RX-API-DMAC7.html)
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP2014518544A5 (cg-RX-API-DMAC7.html)
JP2007508238A5 (cg-RX-API-DMAC7.html)